4-[1-(4-methylphenyl)-1H-pyrrolo[2,3-c]pyridin-3-yl]morpholine | 1427555-65-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯
• 英文名称: 4-[1-(4-methylphenyl)-1H-pyrrolo[2,3-c]pyridin-3-yl]morpholine
• 英文别名: 4-[1-(4-Methylphenyl)pyrrolo[2,3-c]pyridin-3-yl]morpholine；4-[1-(4-methylphenyl)pyrrolo[2,3-c]pyridin-3-yl]morpholine
• CAS: 1427555-65-4
• 化学式: C₁₈H₁₉N₃O
• 分子量: 293.368
• InChiKey: DHVIHXOUWLISGQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  22
• 可旋转键数：
  2
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.28
• 拓扑面积：
  30.3
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  3-硝基吡啶 在 potassium phosphate 、 N-溴代丁二酰亚胺(NBS) 、 copper(l) iodide 、 lithium aluminium tetrahydride 、 偶氮二异丁腈 、 palladium 10% on activated carbon 、 potassium tert-butylate 、 氢气 、 N,N'-二甲基乙二胺 作用下， 以 四氢呋喃 、 甲醇 、 四氯化碳 、 乙酸乙酯 、 N,N-二甲基甲酰胺 、 乙腈 为溶剂， -78.0~170.0 ℃ 、100.0 kPa 条件下， 反应 8.0h， 生成 4-[1-(4-methylphenyl)-1H-pyrrolo[2,3-c]pyridin-3-yl]morpholine
  参考文献：
  名称：

  [EN] NEW ENZYME INHIBITOR COMPOUNDS
  [FR] NOUVEAUX COMPOSÉS INHIBITEURS ENZYMATIQUES

  摘要：

  2- {4- [1- (4-氯苯基)-1H-吡咯并[2,3-c]吡啶-3-基]哌啶-1-基}乙基-1-胺; 3-氨基丙基4- [1- (4-氯苯基)-1H-吡咯并[2,3-c]吡啶-3-基]哌啶-1-羧酸酯; 1- {4- [1- (4-氯苯基)-1H-吡咯并[2,3-c]吡啶-3-基]哌啶-1-基}-4- (二甲基氨基)丁酮; 5-氨基-1- {4- [1- (4-氯苯基)-1H-吡咯并[2,3-c]吡啶-3- 基]哌啶-1-基}戊酮; N- (2-氨基乙基)-4- [1- (4-氯苯基)-1H-吡咯并[2,3-c]吡啶-3-基]哌啶-1-羧酰胺; N- (3-氨基丙基)-4- [1- (4-氯苯基)-1H-吡咯并[2,3-c]吡啶-3-基]哌啶-1-羧酰胺; 4- [1- (4-氯苯基)-1H-吡咯并[2,3- c]吡啶-3-基]-N- [3- (二甲基氨基)丙基]哌啶-1-羧酰胺; 1- ({4- [1- (4- 氯苯基)-1H-吡咯并[2,3-c]吡啶-3-基]哌啶-1-基}羰基)哌嗪; 4- ({4- [1- (4- 氯苯基)-1H-吡咯并[2,3-c]吡啶-3-基]哌啶-1-基}羰基)吗啉; 1- ({4- [1- (4- 氯苯基)-1H-吡咯并[2,3-c]吡啶-3-基]哌啶-1-基}羰基)-1,4-二氮杂辛烷; 乙基1- [1- (4-氯苯基)-1H-吡唑并[3,4-c]吡啶-3-基]哌啶-4-羧酸酯; 乙基1- [1- (4- 甲基苯基)-1H-吡唑并[3,4-c]吡啶-3-基]哌啶-4-羧酸酯; 1- [1- (4- 氯苯基)-1H-吡唑并[3,4-c]吡啶-3-基]哌啶-4-羧酸; N- (2-氨基乙基)-1- [1- (4-氯苯基)-1H-吡唑并[3,4-c]吡啶-3-基]哌啶-4-羧酰胺; 4- ({1- [1- (4-氯苯基)-1H-吡唑并[3,4-c]吡啶-3-基]哌啶-4- 基}羰基)吗啉; 1- ({1- [1- (4-氯苯基)-1H-吡唑并[3,4-c]吡啶-3-基]哌啶- 4-基}羰基)哌嗪; {4- [1- (4-甲基苯基)-1H-吡唑并[3,4-c]吡啶-3-基]吗啉- 3-基}甲醇; {4- [1- (4-甲基苯基)-1H-吡唑并[3,4-c]吡啶-3-基]吗啉-2-基}甲醇; [(3R)-4- [1- (4-氯苯基)-1H-吡唑并[3,4-c]吡啶-3-基]吗啉-3- 基]甲醇; 甲基4- [1- (4-氯苯基)-1H-吡唑并[3,4-c]吡啶-3-基]吗啉-3-羧酸酯; N- (2-氨基乙基)-4- [1- (4-氯苯基)-1H-吡唑并[3,4-c]吡啶-3- 基]吗啉-3-羧酰胺; 2- {4- [1- (4-氯苯基)-1H-吡唑并[3,4-c]吡啶-3- 基]吗啉-3-基}乙基-1-醇; 甲基1- [1- (4-氯苯基)-1H-吡唑并[3,4-c]吡啶-3- 基]哌啶-2-羧酸酯; N- (2-氨基乙基)-1- [1- (4-氯苯基)-1H-吡唑并[3,4- c]吡啶-3-基]哌啶-2-羧酰胺; 1- ({1- [1- (4-氯苯基)-1H-吡唑并[3,4- c]吡啶-3-基]哌啶-2-基}羰基)哌嗪; 4- [1- (4-甲基苯基)-1H-吡咯并[2,3- c]吡啶-3-基]吗啉; 1- (4-氯苯基)-3- (哌啶-4-基)-1H-吡咯并[2,3-c]吡啶-4- 醇; N-丁基-1- (4-氯苯基)-N-甲基-1H-吡唑并[3,4-c]吡啶-3-胺; 1- [4- (氟甲基)苯基]-3- (氧杂环丁基)-1H-吡咯并[3,4-c]吡啶; 和3- ({4- [1- (4- 氯苯基)-1H-吡咯并[3,4-c]吡啶-3-基]哌啶-1-基}甲基)吡啶对于抑制SSAO活性是有用的。

  公开号：

  WO2013037411A1

文献信息

• [EN] VAP-1 INHIBITORS FOR TREATING PAIN<br/>[FR] INHIBITEURS DE VAP-1 POUR LE TRAITEMENT DE LA DOULEUR
  申请人：PROXIMAGEN LTD

  公开号：WO2017098236A1

  公开（公告）日：2017-06-15

  This invention relates to the use of inhibitors of VAP-1/SSAO activity, and pharmaceutical compositions comprising the same, for the treatment of pain; and to a combined preparation comprising an inhibitor of VAP-1/SSAO activity and a steroid, and the use of the combined preparation in medicine, particularly for treatment of pain.

  这项发明涉及使用VAP-1/SSAO活性抑制剂以及包含相同成分的药物组合物，用于治疗疼痛；以及包含VAP-1/SSAO活性抑制剂和类固醇的联合制剂，以及在医学中使用该联合制剂，特别是用于治疗疼痛。
• [EN] NEW ENZYME INHIBITOR COMPOUNDS<br/>[FR] NOUVEAUX COMPOSÉS INHIBITEURS ENZYMATIQUES
  申请人：PROXIMAGEN LTD

  公开号：WO2013037411A1

  公开（公告）日：2013-03-21

  2-4-[1-(4-chlorophenyl)-1H-pyrrolo[2,3-c]pyridin-3-yl]piperidin-1-yl}ethan-1-amine; 3- aminopropyl 4-[1-(4-chlorophenyl)-1H-pyrrolo[2,3-c]pyridin-3-yl]piperidine-1-carboxylate; 1-4-[1-(4-chlorophenyl)-1H-pyrrolo[2,3-c]pyridin-3-yl]piperidin-1-yl}-4- (dimethylamino)butan-1-one; 5-amino-1-4-[1-(4-chlorophenyl)-1H-pyrrolo[2,3-c]pyridin-3- yl]piperidin-1-yl}pentan-1-one; N-(2-aminoethyl)-4-[1-(4-chlorophenyl)-1H-pyrrolo[2,3- c]pyridin-3-yl]piperidine-1-carboxamide; N-(3-aminopropyl)-4-[1-(4-chlorophenyl)-1H- pyrrolo[2,3-c]pyridin-3-yl]piperidine-1-carboxamide; 4-[1-(4-chlorophenyl)-1H-pyrrolo[2,3- c]pyridin-3-yl]-N-[3-(dimethylamino)propyl]piperidine-1-carboxamide; 1-(4-[1-(4- chlorophenyl)-1H-pyrrolo[2,3-c]pyridin-3-yl]piperidin-1-yl}carbonyl)piperazine; 4-(4-[1-(4- chlorophenyl)-1H-pyrrolo[2,3-c]pyridin-3-yl]piperidin-1-yl}carbonyl)morpholine; 1-(4-[1-(4- chlorophenyl)-1H-pyrrolo[2,3-c]pyridin-3-yl]piperidin-1-yl}carbonyl)-1,4-diazepane; ethyl 1- [1-(4-chlorophenyl)-1H-pyrazolo[3,4-c]pyridin-3-yl]piperidine-4-carboxylate; ethyl 1-[1-(4- methylphenyl)-1H-pyrazolo[3,4-c]pyridin-3-yl]piperidine-4-carboxylate; 1-[1-(4- chlorophenyl)-1H-pyrazolo[3,4-c]pyridin-3-yl]piperidine-4-carboxylic acid; N-(2- aminoethyl)-1-[1-(4-chlorophenyl)-1H-pyrazolo[3,4-c]pyridin-3-yl]piperidine-4-carboxamide; 4-(1-[1-(4-chlorophenyl)-1H-pyrazolo[3,4-c]pyridin-3-yl]piperidin-4 yl}carbonyl)morpholine; 1-(1-[1-(4-chlorophenyl)-1H-pyrazolo[3,4-c]pyridin-3-yl]piperidin- 4-yl}carbonyl)piperazine; 4-[1-(4-methylphenyl)-1H-pyrazolo[3,4-c]pyridin-3-yl]morpholin- 3-yl}methanol; 4-[1-(4-methylphenyl)-1H-pyrazolo[3,4-c]pyridin-3-yl]morpholin-2-yl}methanol; [(3R)-4-[1-(4-chlorophenyl)-1H-pyrazolo[3,4-c]pyridin-3-yl]morpholin-3- yl]methanol; methyl 4-[1-(4-chlorophenyl)-1H-pyrazolo[3,4-c]pyridin-3-yl]morpholine-3- carboxylate; N-(2-aminoethyl)-4-[1-(4-chlorophenyl)-1H-pyrazolo[3,4-c]pyridin-3- yl]morpholine-3-carboxamide; 2-4-[1-(4-chlorophenyl)-1H-pyrazolo[3,4-c]pyridin-3- yl]morpholin-3-yl}ethan-1-ol; methyl 1-[1-(4-chlorophenyl)-1H-pyrazolo[3,4-c]pyridin-3- yl]piperidine-2-carboxylate; N-(2-aminoethyl)-1-[1-(4-chlorophenyl)-1H-pyrazolo[3,4- c]pyridin-3-yl]piperidine-2-carboxamide; 1-(1-[1-(4-chlorophenyl)-1H-pyrazolo[3,4- c]pyridin-3-yl]piperidin-2-yl}carbonyl)piperazine; 4-[1-(4-methylphenyl)-1H-pyrrolo[2,3- c]pyridin-3-yl]morpholine; 1-(4-chlorophenyl)-3-(piperidin-4-yl)-1H-pyrrolo[2,3-c]pyridin-4- ol; N-butyl-1-(4-chlorophenyl)-N-methyl-1H-pyrazolo[3,4-c]pyridin-3-amine; 1-[4- (fluoromethyl)phenyl]-3-(oxan-4-yl)-1H-pyrazolo[3,4-c]pyridine; and 3-(4-[1-(4- chlorophenyl)-1H-pyrazolo[3,4-c]pyridin-3-yl]piperidin-1-yl}methyl)pyridine are useful for the inhibition of SSAO activity.

  2- 4- [1- (4-氯苯基)-1H-吡咯并[2,3-c]吡啶-3-基]哌啶-1-基}乙基-1-胺; 3-氨基丙基4- [1- (4-氯苯基)-1H-吡咯并[2,3-c]吡啶-3-基]哌啶-1-羧酸酯; 1- 4- [1- (4-氯苯基)-1H-吡咯并[2,3-c]吡啶-3-基]哌啶-1-基}-4- (二甲基氨基)丁酮; 5-氨基-1- 4- [1- (4-氯苯基)-1H-吡咯并[2,3-c]吡啶-3- 基]哌啶-1-基}戊酮; N- (2-氨基乙基)-4- [1- (4-氯苯基)-1H-吡咯并[2,3-c]吡啶-3-基]哌啶-1-羧酰胺; N- (3-氨基丙基)-4- [1- (4-氯苯基)-1H-吡咯并[2,3-c]吡啶-3-基]哌啶-1-羧酰胺; 4- [1- (4-氯苯基)-1H-吡咯并[2,3- c]吡啶-3-基]-N- [3- (二甲基氨基)丙基]哌啶-1-羧酰胺; 1- (4- [1- (4- 氯苯基)-1H-吡咯并[2,3-c]吡啶-3-基]哌啶-1-基}羰基)哌嗪; 4- (4- [1- (4- 氯苯基)-1H-吡咯并[2,3-c]吡啶-3-基]哌啶-1-基}羰基)吗啉; 1- (4- [1- (4- 氯苯基)-1H-吡咯并[2,3-c]吡啶-3-基]哌啶-1-基}羰基)-1,4-二氮杂辛烷; 乙基1- [1- (4-氯苯基)-1H-吡唑并[3,4-c]吡啶-3-基]哌啶-4-羧酸酯; 乙基1- [1- (4- 甲基苯基)-1H-吡唑并[3,4-c]吡啶-3-基]哌啶-4-羧酸酯; 1- [1- (4- 氯苯基)-1H-吡唑并[3,4-c]吡啶-3-基]哌啶-4-羧酸; N- (2-氨基乙基)-1- [1- (4-氯苯基)-1H-吡唑并[3,4-c]吡啶-3-基]哌啶-4-羧酰胺; 4- (1- [1- (4-氯苯基)-1H-吡唑并[3,4-c]吡啶-3-基]哌啶-4- 基}羰基)吗啉; 1- (1- [1- (4-氯苯基)-1H-吡唑并[3,4-c]吡啶-3-基]哌啶- 4-基}羰基)哌嗪; 4- [1- (4-甲基苯基)-1H-吡唑并[3,4-c]吡啶-3-基]吗啉- 3-基}甲醇; 4- [1- (4-甲基苯基)-1H-吡唑并[3,4-c]吡啶-3-基]吗啉-2-基}甲醇; [(3R)-4- [1- (4-氯苯基)-1H-吡唑并[3,4-c]吡啶-3-基]吗啉-3- 基]甲醇; 甲基4- [1- (4-氯苯基)-1H-吡唑并[3,4-c]吡啶-3-基]吗啉-3-羧酸酯; N- (2-氨基乙基)-4- [1- (4-氯苯基)-1H-吡唑并[3,4-c]吡啶-3- 基]吗啉-3-羧酰胺; 2- 4- [1- (4-氯苯基)-1H-吡唑并[3,4-c]吡啶-3- 基]吗啉-3-基}乙基-1-醇; 甲基1- [1- (4-氯苯基)-1H-吡唑并[3,4-c]吡啶-3- 基]哌啶-2-羧酸酯; N- (2-氨基乙基)-1- [1- (4-氯苯基)-1H-吡唑并[3,4- c]吡啶-3-基]哌啶-2-羧酰胺; 1- (1- [1- (4-氯苯基)-1H-吡唑并[3,4- c]吡啶-3-基]哌啶-2-基}羰基)哌嗪; 4- [1- (4-甲基苯基)-1H-吡咯并[2,3- c]吡啶-3-基]吗啉; 1- (4-氯苯基)-3- (哌啶-4-基)-1H-吡咯并[2,3-c]吡啶-4- 醇; N-丁基-1- (4-氯苯基)-N-甲基-1H-吡唑并[3,4-c]吡啶-3-胺; 1- [4- (氟甲基)苯基]-3- (氧杂环丁基)-1H-吡咯并[3,4-c]吡啶; 和3- (4- [1- (4- 氯苯基)-1H-吡咯并[3,4-c]吡啶-3-基]哌啶-1-基}甲基)吡啶对于抑制SSAO活性是有用的。
• VAP-1 INHIBITORS FOR TREATING PAIN
  申请人：BenevolentAI Cambridge Limited

  公开号：EP3777846A1

  公开（公告）日：2021-02-17

  This invention relates to the use of inhibitors of VAP-1/SSAO activity, and pharmaceutical compositions comprising the same, for the treatment of pain; and to a combined preparation comprising an inhibitor of VAP-1/SSAO activity and a steroid, and the use of the combined preparation in medicine, particularly for treatment of pain.

  本发明涉及 VAP-1/SSAO 活性抑制剂和包含 VAP-1/SSAO 活性抑制剂的药物组合物在治疗疼痛中的应用；还涉及一种包含 VAP-1/SSAO 活性抑制剂和类固醇的组合制剂，以及该组合制剂在医学中的应用，特别是在治疗疼痛中的应用。
• NEW THERAPEUTIC USES OF ENZYME INHIBITORS
  申请人：PROXIMAGEN LIMITED

  公开号：US20160113893A1

  公开（公告）日：2016-04-28

  The invention relates to use of compounds which inhibit VAP-1/SSAO activity for the treatment of muscular dystrophy.
• Therapeutic uses of enzyme inhibitors
  申请人：Proximagen Limited

  公开号：US20160101072A1

  公开（公告）日：2016-04-14

  The invention relates to use of compounds which inhibit VAP-1/SSAO activity for the treatment of muscular dystrophy. The invention also relates to combined preparations comprising compounds which inhibit VAP-1/SSAO activity, and their use for the treatment of muscular dystrophy.